Clinical Trials
- Endocrine System, Genetics
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)
- Ages18 years - 60 years
- GenderBoth
- Genetics
Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects
- Ages12 years and older
- GenderBoth
- Liver, Vision/Eye, Brain, Spinal Cord & Nervous System
Wilson Disease Registry
- GenderBoth